Previous 10 | Next 10 |
2023-10-27 06:11:42 ET Summary Edwards Lifesciences delivered 10.9% organic revenue growth and reiterated full-year guidance, boosting confidence in their $10 billion revenue opportunity by 2028. Clinical trial updates show excellent survival rates for patients receiving the SAPIE...
2023-10-26 18:15:44 ET Although Edwards Lifesciences (NYSE: EW) performed more or less in line with analyst expectations in its most recently completed quarter, the company's guidance left something to be desired. Unfortunately for the medical device maker, its third-quarter earning...
2023-10-26 17:21:03 ET Summary Third quarter results from Edwards Lifesciences don't really add much to the bull or bear case, with a small miss (but double-digit growth) in TAVR, and guidance for double-digit growth. Recent presentations from the annual TCT meeting may not look g...
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION PR Newswire SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID...
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION PR Newswire SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) t...
2023-10-26 08:35:12 ET More on Golden Minerals, Opendoor Technologies, etc. Opendoor Technologies Inc. (OPEN) Goldman Sachs 2023 Communacopia & Technology Conference Transcript Opendoor: The Bottom May Be Here For The Brave Rentokil Initial: Thriving Compounder I...
2023-10-26 01:40:10 ET Edwards Lifesciences Corporation (EW) Q3 2023 Earnings Conference Call October 25, 2023 05:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President, TAV...
2023-10-25 16:24:49 ET More on Edwards Lifesciences Edwards Lifesciences: Rising Dominance In Structural Heart Disease Edwards Lifesciences Q3 2023 Earnings Preview Edwards Lifesciences posts 5-year data for Sapien 3 heart valve Seeking Alpha’s Qu...
St. Joe Company (The) (JOE) is expected to report for Q1 2024 Meta Platforms Inc. (META) is expected to report $3.62 for Q3 2023 Industrial Logistics Properties Trust (ILPT) is expected to report $0.11 for Q3 2023 Mid-America Apartment Communities Inc. (MAA) is expected to report $2.2...
Edwards Lifesciences Corporation (EW) is expected to report $0.59 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this update in regard to the status of the proposed return of capital announced on June 19, 2024 . The Company has prepared and mailed its ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
2024-07-25 16:00:08 ET Pito Chickering from Deutsche Bank issued a price target of $85.00 for EW on 2024-07-25 13:36:00. The adjusted price target was set to $85.00. At the time of the announcement, EW was trading at $60.58. The overall price target consensus is at $109....